albuterol (Armstrong Albuterol HFA) vs Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol (Armstrong Albuterol HFA)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00634829 · Phase 3 · terminated
This is a randomized, quadruple-blind, placebo- and active-controlled crossover study measuring lung function directly, but the sample size is small and no results have been posted yet, so the outcome remains unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Next expected readout: April 2028 · NCT07426458 (registry estimate)
No aligned efficacy figure on record for this race.
Vilanterol
Developed by GlaxoSmithKline
NCT00381667 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, but enrolled only 14 participants. Its primary outcomes included lung-function and safety measurements rather than a hard clinical endpoint, and the primary comparison cannot be assessed because results have not been posted.
Reported efficacy
Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036) (mixed)
Result source: NCT00600171
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | albuterol (Armstrong Albuterol HFA) | Vilanterol |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT00667407 | —Not reported |
| Trough FEV1, change | —Not posted · NCT00667407 | 0.3 vs 0.1+0.1 vs placeboNCT006001718 other results
|
| ACQ-5, change | —Not posted · NCT00667407 | —Not reported |
| OCS dose reduction | —Not posted · NCT00667407 | —Not reported |
Severe exacerbations, annualised rate
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- Vilanterol
- —Not reported
Trough FEV1, change
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- Vilanterol
- 0.3 vs 0.1+0.1 vs placeboNCT00600171
8 other results
- 0.3 vs 0.1 NCT00600171
- 0.3 vs 0.1 NCT00600171
- 0.2 vs 0.1 NCT00600171
- 0.2 vs 0.1 NCT00600171
- -0.5 vs -0.8 NCT01128569
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
ACQ-5, change
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- Vilanterol
- —Not reported
OCS dose reduction
- albuterol (Armstrong Albuterol HFA)
- —Not posted · NCT00667407
- Vilanterol
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
albuterol (Armstrong Albuterol HFA): registry results are on file for Asthma, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. albuterol (Armstrong Albuterol HFA): 0 of 4 rows · Vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Vilanterol |
|---|---|
| Dropout rate | 7.9%25 µga NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results4.9%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 9.9%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 16.8%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12.2%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence 21.1%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 12.4%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 18.4%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —25 µg NCT01453296 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1%25 µga NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results0%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 1%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.9%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence 0.9%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —25 µg NCT01453296 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%25 µga NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results0%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.9%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence —25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence 0%100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence 0%25 µg NCT01453296 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 25 µga headache 6.9% (placebo 7.8%) upper respiratory tract infection 2% (placebo 2%) nasopharyngitis 0% (placebo 3.9%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 13 more results50 µg headache 7.8% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 2% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12.5 µg headache 9% (placebo 7.8%) upper respiratory tract infection 3% (placebo 2%) nasopharyngitis 0% (placebo 3.9%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 6.25 µg headache 6.9% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 1% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 3 µg headache 11.9% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 2% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 25 µg OD headache 8.7% (placebo 4.3%) nasopharyngitis 7.8% (placebo 10.3%) oropharyngeal pain 5.2% (placebo 6%) NCT01181895 · Phase 3 · registry result, not featured evidence 12.5 OD nasopharyngitis 8.8% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 25 OD nasopharyngitis 7.9% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 6.25 OD nasopharyngitis 7% (placebo 7%) headache 5.3% (placebo 3.5%) influenza 3.5% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 100/25 µg AM headache 25% (placebo 26.1%) nasopharyngitis 12.5% (placebo 13%) dysmenorrhoea 4.2% (placebo 0%) NCT01287065 · Phase 2 · registry result, not featured evidence 100/25 µg PM headache 32% (placebo 26.1%) gastroenteritis 8% (placebo 0%) nasopharyngitis 8% (placebo 13%) NCT01287065 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 55.6% (placebo 40.7%) nasopharyngitis 11.1% (placebo 7.4%) oropharyngeal pain 11.1% (placebo 7.4%) NCT01128595 · Phase 2 · registry result, not featured evidence 25 µg upper respiratory tract infection 11.1% (placebo 0%) headache 7.4% (placebo 7.7%) pyrexia 7.4% (placebo 0%) NCT01453296 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 9.8% (placebo 17.6%) dysphonia 3.9% (placebo 0%) mouth ulceration 3.9% (placebo 0%) NCT01128569 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 12 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Vilanterol
show 8 more results
show 9 more results
show 5 more results
show 5 more results
show 4 more results
show 4 more results
show 2 more results
show 3 more results
show 3 more results
show 5 more results
show 5 more results
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Armstrong Albuterol HFA)'s landscape · Vilanterol's landscape